The New Medicare GLP-1 Bridge Program Explained

For years, one of the biggest frustrations for Medicare patients struggling with obesity has been the lack of coverage for FDA-approved weight loss medications like Wegovy and Zepbound. While many commercial insurance plans began expanding coverage, Medicare beneficiaries were often left paying out of pocket — sometimes more than $1,000 per month.

That is finally beginning to change.

Starting July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) will launch a new temporary demonstration program called the Medicare GLP-1 Bridge Program, designed to give eligible Medicare beneficiaries access to certain GLP-1 medications for obesity treatment at a significantly reduced cost.

What Is the Medicare GLP-1 Bridge Program?

The Medicare GLP-1 Bridge Program is a short-term federal demonstration project that provides qualifying Medicare Part D beneficiaries with access to certain FDA-approved GLP-1 medications for weight management.

This program was created as a “bridge” to a larger long-term obesity treatment initiative called the BALANCE Model, which Medicare plans to expand further in the future. Unlike traditional Medicare drug coverage, this GLP-1 Bridge program operates separately from the normal Part D insurance process. CMS will use a centralized system to manage prior authorizations, pharmacy claims, and payment processing.

When Does the Program Start?

The program officially begins on July 1, 2026.

Current CMS guidance states the program is expected to continue through December 31, 2027.

Which Medications Will Be Covered?

At this time, CMS has announced coverage for the following GLP-1 medications when prescribed specifically for obesity treatment and weight maintenance:

• Wegovy

• Zepbound (KwikPen formulation only)

• Foundayo

  
  

How Much Will It Cost?

One of the biggest headlines surrounding the program is the dramatically reduced monthly cost.

Eligible patients are expected to pay approximately $50 per month for covered medications — a major reduction compared to standard retail pricing. For many Medicare patients who previously could not afford treatment, this could be life-changing access to obesity care.

Who Is Eligible for the Medicare GLP-1 Bridge Program?

Not all Medicare beneficiaries will automatically qualify for the new GLP-1 Bridge Program. CMS has established specific eligibility criteria that must be documented through a prior authorization process.

To qualify, patients must:

• Be enrolled in a qualifying Medicare Part D or Medicare Advantage prescription drug plan

• Have a healthcare provider submit a prior authorization request

• Use the medication alongside ongoing lifestyle modification, including nutrition and physical activity counseling

In addition, patients must meet ONE of the following clinical pathways at the time they originally started GLP-1 therapy:

Pathway 1

• BMI ≥35

Pathway 2

• BMI ≥30 PLUS at least one of the following:

  • Heart failure with preserved ejection fraction (HFpEF)

  • Uncontrolled hypertension despite treatment with two blood pressure medications

  • Chronic kidney disease stage 3a or higher

Pathway 3

• BMI ≥27 PLUS at least one of the following:

  • Prediabetes

  • Prior heart attack

  • Prior stroke

  • Symptomatic peripheral artery disease

Importantly, CMS states that eligibility is based on the patient’s BMI and medical status at the time GLP-1 therapy was initiated — not necessarily their current BMI after successful weight loss. This is especially important for patients already taking GLP-1 medications who may now fall into a lower BMI category due to treatment success.

Will Patients Need Prior Authorization?

Yes.

Providers will still need to submit a prior authorization request documenting that the patient meets CMS criteria. However, the authorization process will go through a centralized CMS processor rather than directly through the patient’s Part D insurance plan. This means physician documentation will remain extremely important.

Why This Matters

Obesity is a chronic medical disease — not simply a lifestyle issue or cosmetic concern.

We now have extensive evidence showing that GLP-1 medications can help improve:

• Weight-related complications

• Cardiovascular risk

• Sleep apnea

• Prediabetes and insulin resistance

• Mobility and quality of life

For many older adults, access to these medications has simply been financially out of reach.

The Medicare GLP-1 Bridge Program represents one of the biggest policy shifts we have seen in obesity medicine and may help thousands of Medicare patients finally gain access to evidence-based obesity treatment.

Important Limitations to Understand

While this is exciting news, there are still some important caveats:

• Not every Medicare beneficiary will automatically qualify

• Prior authorization requirements still apply

• Coverage rules may evolve over time

• The program is currently temporary

• Long-term coverage after 2027 remains uncertain

Patients interested in the program should begin discussing eligibility, documentation, and treatment goals with their healthcare provider now so they are prepared once the program launches.

Final Thoughts

The launch of the Medicare GLP-1 Bridge Program signals a major shift in how obesity is viewed and treated within healthcare policy. For many patients, this may finally open the door to treatment that was previously inaccessible due to cost. As obesity medicine continues to evolve, we are hopeful to see increasing recognition that obesity deserves the same evidence-based, compassionate medical care as any other chronic disease.

---

About Cardona Direct Primary Care

At Cardona Direct Primary Care, Dr. Cardona and Dr. Garland provide personalized healthcare, including direct primary care, obesity medicine, and aesthetic treatments. Dr. Cardona is board-certified in both family medicine and obesity medicine and has a special interest in medical weight loss. Dr. Garland is board-certified in family medicine and is a certified medical marijuana provider. She has a special interest in skincare and is eager to assist with your individual skincare needs. Located in Jacksonville, FL, we are dedicated to prioritizing you. Contact us at 904-551-4625 or visit our website at www.cardonadpc.com to learn more and schedule your appointment today!